» Articles » PMID: 15784827

Impact of Cancer Treatment on Uterine Function

Overview
Specialty Oncology
Date 2005 Mar 24
PMID 15784827
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Fertility and future pregnancy potential are of concern to survivors of childhood cancer. Radiotherapy causes both ovarian and uterine damage. There are no reports of uterine damage after chemotherapy. The magnitude of risk is related to age at treatment, dose, and schedule. The dose of radiation required to destroy fifty percent of immature oocytes is <2 Gy. Reduced ovarian volume and low inhibin B and anti-Mullerian hormone concentrations in survivors with regular menses may be markers of incipient ovarian failure. Uterine damage, manifest by impaired growth and blood flow, is a likely consequence of pelvic irradiation. Uterine volume correlates with age at irradiation. Exposure of the pelvis to radiation is associated with an increased risk of miscarriage, midtrimester pregnancy loss, preterm birth, and low birthweight. The optimal dose and delivery route of estrogen replacement required to facilitate uterine growth in adolescent women treated with total body irradiation in childhood needs to be established. If female survivors of childhood cancer do achieve a pregnancy, then these pregnancies are high risk, pose a challenge for optimal mode of delivery, and require a multidisciplinary approach to management.

Citing Articles

Uterus transplantation: A clinical breakthrough after systematic preclinical research.

Brannstrom M, Milenkovic M, Tsakos E Reprod Med Biol. 2025; 24(1):e12636.

PMID: 39935690 PMC: 11811759. DOI: 10.1002/rmb2.12636.


Live birth from ovarian grafted tissue after pelvic radiation for rectal cancer.

Rozen G, Chander S, Polyakov A, Thevathasan I, Stern C F S Rep. 2024; 5(2):214-218.

PMID: 38983737 PMC: 11228876. DOI: 10.1016/j.xfre.2024.04.004.


Fertility-sparing uterine displacement for pelvic malignancies: surgical options and radiotherapy dosimetry on a human cadaver.

Pavone M, Waeldin L, Seeliger B, Bizzarri N, Mutter D, Jarnet D World J Surg Oncol. 2024; 22(1):147.

PMID: 38831328 PMC: 11145884. DOI: 10.1186/s12957-024-03423-4.


Advantages and limitations of estrogen replacement therapy on hypogonadal survivors of childhood cancer.

Nakamura M, Ohba T, Sasaki R, Saito F, Yamaguchi M, Motohara T Int J Clin Oncol. 2023; 28(11):1563-1572.

PMID: 37646971 DOI: 10.1007/s10147-023-02405-y.


Reproductive Results in Cancer Survivors after Fertility Sparing Management: The Need for the Standardization of Definitions.

Piatek S, Szymusik I, Bidzinski M Cancers (Basel). 2023; 15(14).

PMID: 37509232 PMC: 10377228. DOI: 10.3390/cancers15143569.